Publication:
Free Text: The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma.


abstract

BACKGROUND:

cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. ipilimumab is a monoclonal antibody directed against CTLA-4.

OBJECTIVE:

This review describes the basic mechanism of ipilimumab and discusses data available to date with regards to its safety and efficacy profile.

METHODS:

Data from clinical trials including abstracts was reviewed using the PubMed Database, as well as the American Society of Clinical Oncology Abstract Database.

CONCLUSION:

CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and has efficacy as a therapeutic agent in a variety of cancers. The classical response interpretation has changed because of the delayed mechanism of action. The toxicities are autoimmune events and guidelines for treatment of these effects are discussed. Therapy with ipilimumab leads to durable responses. The first two Phase III randomized studies showed an improvement of survival at 1, 2, and 3 years. Other studies are currently underway to better understand the optimal treatment administration of ipilimumab in melanoma.

Related Articles
Review The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.
Expert Opin Biol Ther. 2009
Review The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.
Movva S, Verschraegen C. Expert Opin Biol Ther. 2009 Feb; 9(2):231-41.
Review Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Oncologist. 2007
Review Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J. Oncologist. 2007 Jul; 12(7):864-72.
Review Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Curr Top Med Chem. 2012
Review Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M, Testori A, Ferucci PF. Curr Top Med Chem. 2012; 12(1):61-6.
Review Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Pharmacol Res. 2012
Review Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G, Tentori L, Navarra P. Pharmacol Res. 2012 Jan; 65(1):9-22. Epub 2011 Sep 10.
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Cancer Immunol Immunother. 2009
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, et al. Cancer Immunol Immunother. 2009 Aug; 58(8):1297-306. Epub 2009 Jan 13.